Literature DB >> 30416848

N6-methyladenine RNA modification and cancers.

Xia Wu1, Lina Sang1, Yuping Gong1.   

Abstract

Similar to DNA methylation modifications, N6-methyladenine (m6A) has been identified as a dynamic and reversible modification in messenger RNA (mRNA), regulated by m6A methyltransferases and demethylases. m6A modifications regulate gene expressions and play vital roles in many life processes. Some proteins serve as m6A-binding proteins to perform the m6A-modified biological functions. Recently, m6A modifications have been reported to play critical roles in human cancers, including lung cancer, brain tumor, leukemia, and many others. In this comprehensive review, we have described the roles played by m6A modifications of mRNA in the development of cancers. These modifications appear to have an oncogenic role in some cancers while a tumor-suppressor role in others. Therefore, it would be of great significance to study the biological functions of genes regulated by m6A in different cancers and identify the key m6A target genes to understand the potential mechanism underlying the pathogenesis of cancer.

Entities:  

Keywords:  N6-methyladenine (m6A); RNA epigenetics; cancer; demethylases; methyltransferases

Year:  2018        PMID： 30416848      PMCID： PMC6220143     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  55 in total

1.  N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.

Authors:  Xiao Wang; Boxuan Simen Zhao; Ian A Roundtree; Zhike Lu; Dali Han; Honghui Ma; Xiaocheng Weng; Kai Chen; Hailing Shi; Chuan He
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

2.  m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells.

Authors:  Pedro J Batista; Benoit Molinie; Jinkai Wang; Kun Qu; Jiajing Zhang; Lingjie Li; Donna M Bouley; Ernesto Lujan; Bahareh Haddad; Kaveh Daneshvar; Ava C Carter; Ryan A Flynn; Chan Zhou; Kok-Seong Lim; Peter Dedon; Marius Wernig; Alan C Mullen; Yi Xing; Cosmas C Giallourakis; Howard Y Chang
Journal:  Cell Stem Cell       Date:  2014-10-16       Impact factor: 24.633

3.  WTAP is a novel oncogenic protein in acute myeloid leukemia.

Authors:  H Bansal; Q Yihua; S P Iyer; S Ganapathy; D A Proia; D Proia; L O Penalva; P J Uren; U Suresh; J S Carew; A B Karnad; S Weitman; G E Tomlinson; M K Rao; S M Kornblau; S Bansal
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

4.  Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons.

Authors:  Kate D Meyer; Yogesh Saletore; Paul Zumbo; Olivier Elemento; Christopher E Mason; Samie R Jaffrey
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

5.  YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA.

Authors:  Hailing Shi; Xiao Wang; Zhike Lu; Boxuan S Zhao; Honghui Ma; Phillip J Hsu; Chang Liu; Chuan He
Journal:  Cell Res       Date:  2017-01-20       Impact factor: 25.617

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.

Authors:  Yin Li; Kai Chen; Yong Zhou; Yiren Xiao; Manman Deng; Zhiwu Jiang; Wei Ye; Xiangmeng Wang; Xinru Wei; Jie Li; Jiabao Liang; Zhongxin Zheng; Yao Yao; Weiguang Wang; Peng Li; Bing Xu
Journal:  Curr Cancer Drug Targets       Date:  2015       Impact factor: 3.428

8.  The RNA Modification Database, RNAMDB: 2011 update.

Authors:  William A Cantara; Pamela F Crain; Jef Rozenski; James A McCloskey; Kimberly A Harris; Xiaonong Zhang; Franck A P Vendeix; Daniele Fabris; Paul F Agris
Journal:  Nucleic Acids Res       Date:  2010-11-10       Impact factor: 16.971

9.  The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.

Authors:  Xiao Li; Jingyuan Tang; Wen Huang; Feng Wang; Pu Li; Chao Qin; Zhiqiang Qin; Qing Zou; Jifu Wei; Lixin Hua; Haiwei Yang; Zengjun Wang
Journal:  Oncotarget       Date:  2017-10-10

10.  DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells.

Authors:  Xiaotian Zhang; Jianzhong Su; Mira Jeong; Myunggon Ko; Yun Huang; Hyun Jung Park; Anna Guzman; Yong Lei; Yung-Hsin Huang; Anjana Rao; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2016-07-18       Impact factor: 38.330
View more
  16 in total

1.  Low Molecular Pectin Inhibited the Lipid Accumulation by Upregulation of METTL7B.

Authors:  Xiaojin Yang; Yinghua Yuan; Desheng Xie
Journal:  Appl Biochem Biotechnol       Date:  2021-01-23       Impact factor: 2.926

Review 2.  N6-methyladenine RNA modification and cancer.

Authors:  Jun Yang; Junwen Chen; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

3.  Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.

Authors:  Na Li; Xianquan Zhan
Journal:  EPMA J       Date:  2020-07-29       Impact factor: 6.543

4.  Peripheral Blood Leukocyte N6-methyladenosine is a Noninvasive Biomarker for Non-small-cell Lung Carcinoma.

Authors:  Yuqing Pei; Xiaoying Lou; Kexin Li; Xiaotian Xu; Ye Guo; Danfei Xu; Zhenxi Yang; Dongsheng Xu; Wei Cui; Donghong Zhang
Journal:  Onco Targets Ther       Date:  2020-11-19       Impact factor: 4.147

5.  mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis.

Authors:  Elodie Villa; Umakant Sahu; Brendan P O'Hara; Eunus S Ali; Kathryn A Helmin; John M Asara; Peng Gao; Benjamin D Singer; Issam Ben-Sahra
Journal:  Mol Cell       Date:  2021-03-22       Impact factor: 17.970

Review 6.  N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases.

Authors:  Ye-Shi Chen; Xin-Ping Ouyang; Xiao-Hua Yu; Petr Novák; Le Zhou; Ping-Ping He; Kai Yin
Journal:  J Cardiovasc Transl Res       Date:  2021-02-25       Impact factor: 4.132

Review 7.  Regulation of RNA N6-methyladenosine modification and its emerging roles in skeletal muscle development.

Authors:  Jiju Li; Yangli Pei; Rong Zhou; Zhonglin Tang; Yalan Yang
Journal:  Int J Biol Sci       Date:  2021-04-12       Impact factor: 6.580

8.  METTL3 Attenuates LPS-Induced Inflammatory Response in Macrophages via NF-κB Signaling Pathway.

Authors:  Jinghua Wang; Shushan Yan; Hongying Lu; Shufeng Wang; Donghua Xu
Journal:  Mediators Inflamm       Date:  2019-10-24       Impact factor: 4.711

9.  MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool.

Authors:  Emma Rose Scaletti; Karl S Vallin; Lars Bräutigam; Antonio Sarno; Ulrika Warpman Berglund; Thomas Helleday; Pål Stenmark; Ann-Sofie Jemth
Journal:  J Biol Chem       Date:  2020-03-06       Impact factor: 5.157

Review 10.  Non-Coding RNAs in Lung Tumor Initiation and Progression.

Authors:  Ruben Mercado Santos; Cerena Moreno; Wen Cai Zhang
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.